CRSP vs. EDIT

Last updated Aug 1, 2026

CRSP (CRISPR Therapeutics AG) and EDIT (Editas Medicine, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, CRSP returned -16.89%/yr vs -42.73%/yr for EDIT. Their 0.66 correlation means they have sometimes moved together and sometimes differently.

Performance

CRSP vs. EDIT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in CRISPR Therapeutics AG (CRSP) and Editas Medicine, Inc. (EDIT). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, CRSP achieves a -8.49% return, which is significantly lower than EDIT's 25.85% return.

CRSP

• 1D: -0.93%
• 1M: -20.12%
• 6M: -3.94%
• YTD: -8.49%
• 1Y: -14.44%
• 3Y*: -5.25%
• 5Y*: -16.89%
• 10Y*: —
• ALL TIME*: 12.63%

EDIT

• 1D: -4.09%
• 1M: -29.32%
• 6M: 29.65%
• YTD: 25.85%
• 1Y: 5.74%
• 3Y*: -33.19%
• 5Y*: -42.73%
• 10Y*: -20.31%
• ALL TIME*: -16.91%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison

Position	Avg. Volume Value (2W)	Avg. Volume Value (1M)	Avg. Volume Value (3M)
CRSP CRISPR Therapeutics AG	$77.21M	$89.27M	$90.29M
EDIT Editas Medicine, Inc.	$3.37M	$6.15M	$7.58M

CRSP vs. EDIT - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
CRSP CRISPR Therapeutics AG	-8.49%	33.23%	-37.12%	54.00%	-46.36%	-50.51%	151.39%	113.18%	21.68%	15.89%
EDIT Editas Medicine, Inc.	25.85%	61.42%	-87.46%	14.21%	-66.59%	-62.13%	136.78%	30.15%	-25.97%	89.34%

Correlation

The correlation between CRSP and EDIT is 0.63, which is moderate. They have sometimes moved together and sometimes differently, sharing some price drivers without tracking each other closely.

	Correlation
Correlation (1Y) Focuses on recent behavior, but can change the most.	0.63
Correlation (3Y) Balances recent behavior with more history.	0.67
Correlation (5Y) Shows whether the relationship held over a longer period.	0.70
Correlation (All Time) Calculated using the full available price history since Oct 19, 2016	0.66

The correlation between CRSP and EDIT has been stable across timeframes, ranging from 0.63 to 0.70 - a consistent structural relationship.

Fundamentals

Market Cap CRSP : $4.63B EDIT : $252.58M
EPS CRSP : -$6.15 EDIT : -$1.18
PS Ratio CRSP : 1.08K EDIT : 6.64
PB Ratio CRSP : 2.54 EDIT : 57.29
Total Revenue (TTM) CRSP : $4.10M EDIT : $35.86M
Gross Profit (TTM) CRSP : -$171.17M EDIT : $35.86M
EBITDA (TTM) CRSP : -$509.21M EDIT : -$76.66M

Return for Risk

CRSP vs. EDIT — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

CRSP

CRSP Risk / Return Rank: 34
CRSP Sharpe Ratio Rank: 33
CRSP Sortino Ratio Rank: 34
CRSP Omega Ratio Rank: 34
CRSP Calmar Ratio Rank: 33
CRSP Martin Ratio Rank: 35

EDIT

EDIT Risk / Return Rank: 48
EDIT Sharpe Ratio Rank: 46
EDIT Sortino Ratio Rank: 53
EDIT Omega Ratio Rank: 50
EDIT Calmar Ratio Rank: 46
EDIT Martin Ratio Rank: 46

The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

CRSP vs. EDIT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for CRISPR Therapeutics AG (CRSP) and Editas Medicine, Inc. (EDIT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	CRSP	EDIT	Difference
Sharpe ratio: Return per unit of total volatility	-0.25	0.03	-0.28
Sortino ratio: Return per unit of downside risk	0.03	0.76	-0.73
Omega ratio: Gain probability vs. loss probability	1.00	1.09	-0.08
Calmar ratio: Return relative to maximum drawdown	-0.35	0.05	-0.40
Martin ratio: Return relative to average drawdown	-0.54	0.08	-0.62

CRSP vs. EDIT - Sharpe Ratio Comparison

The current CRSP Sharpe Ratio is -0.25, which is lower than the EDIT Sharpe Ratio of 0.03. The chart below compares the historical Sharpe Ratios of CRSP and EDIT, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

CRSP vs. EDIT - Drawdown Comparison

The maximum CRSP drawdown since its inception was -85.11%, smaller than the maximum EDIT drawdown of -98.92%. Use the drawdown chart below to compare losses from any high point for CRSP and EDIT.

Drawdown Indicators

	CRSP	EDIT	Difference
Max Drawdown Largest peak-to-trough decline	-85.11%	-98.92%	+13.81%
Max Drawdown (1Y) Largest decline over 1 year	-42.25%	-59.88%	+17.63%
Max Drawdown (3Y) Largest decline over 3 years	-64.91%	-91.18%	+26.27%
Max Drawdown (5Y) Largest decline over 5 years	-77.31%	-98.66%	+21.35%
Max Drawdown (10Y) Largest decline over 10 years	—	-98.92%	—
Current Drawdown Current decline from peak	-77.15%	-97.15%	+20.00%
Average Drawdown Average peak-to-trough decline	-49.59%	-63.06%	+13.47%
Ulcer Index Depth and duration of drawdowns from previous peaks	27.26%	34.68%	-7.42%

Volatility

CRSP vs. EDIT - Volatility Comparison

The current volatility for CRISPR Therapeutics AG (CRSP) is 14.89%, while Editas Medicine, Inc. (EDIT) has a volatility of 19.89%. This indicates that CRSP experiences smaller price fluctuations and is considered to be less risky than EDIT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	CRSP	EDIT	Difference
Volatility (1M) Calculated over the trailing 1-month period	14.89%	19.89%	-5.00%
Volatility (6M) Calculated over the trailing 6-month period	42.58%	62.54%	-19.96%
Volatility (1Y) Calculated over the trailing 1-year period	58.68%	90.40%	-31.72%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	60.64%	93.71%	-33.07%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	64.15%	83.98%	-19.83%

Dividends

CRSP vs. EDIT - Dividend Comparison

Neither CRSP nor EDIT has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both CRSP and EDIT in my portfolio?

CRSP and EDIT have a correlation of 0.63, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, CRSP or EDIT?

EDIT has higher volatility (19.89%) compared to CRSP (14.89%). In terms of maximum drawdown, CRSP dropped -85.11% vs EDIT's -98.92%.

Which has better risk-adjusted returns?

EDIT currently has the higher Sharpe Ratio (0.03 vs -0.25), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.